Effects of camonagrel, a selective inhibitor of platelet thromboxane synthase, on the platelet-subendothelium interaction

Pharmacology

Volumn 69, Issue 1, 2003, Pages 44-50

  Villalobos, M A ^a   De La Cruz, J P ^a   Escalante, R ^a   Arrebola, M M ^a   Guerrero, A ^a   Sanchez De La Cuesta F ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Acetylsalicylic acid; Camonagrel; Dazoxiben; Subendothelium; Thromboxane A2; Thromboxane synthase inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CAMONAGREL; COLLAGEN; DAZOXIBEN; PROSTAGLANDIN E2; PROSTAGLANDIN F1 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2; THROMBOXANE SYNTHASE INHIBITOR;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HEMOPERFUSION; HUMAN; HUMAN CELL; IC 50; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; ANIMALS; ASPIRIN; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INDANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PROSTAGLANDINS; PROSTAGLANDINS E; RABBITS; THROMBOSIS; THROMBOXANE B2; THROMBOXANE-A SYNTHASE; TUNICA INTIMA;

EID: 0043175383     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071266     Document Type: Article

References (26)

1. 2 from prostaglandin endoperoxides. Nature 1976;261:558-560.
2. Bunting S, Gryglewski R, Moncada S, Vane JR: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976;12:897-913.
3. 1α formation by thromboxane synthase inhibitors in the rats. Thromb Res 1983;32:15-27.
4. Mayeux PR, Kadowitz PJ, McNamara DB: Evidence for a bi-directional prostaglandin endoperoxide shunt between platelets and the bovine coronary artery. Biochim Biophys Acta 1989;1011:18-24.
5. Jones EW, Cockbill SR, Cowley AJ, Hanley SP, Heptinstall S: Effects of dazoxiben and low-dose aspirin on platelet behaviour in man. Br J Clin Pharmacol 1983;15:39-44.
6. Tayler HM, Saxton CA, Parry MJ: Administration to man of UK 37.248-01, a selective inhibitor of thromboxane synthase. Lancet 1981;i:629-632.
7. 2 for their receptors are similar in washed human platelets. Biochem Biophys Res Commun 1988;157:733-739.
8. Gryglewski RJ, Szczeklik A, Korbut R, Swies J, Musial J, Krzanowski M, Maga P: The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel - a new thromboxane synthase inhibitor. Wien Klin Wochenschr 1995;107:283-289.
9. Korbut R, Grygleski RJ: A paradox of thrombogenesis by streptokinase and its prevention by iloprost and camonagrel. Methods Find Exp Clin Pharmacol 1996;18:167-174.
10. Korbut R, Gryglewski RJ: The effect of prostacyclin and nitric oxide on deformability of red blood cells in septic shock in rats. J Physiol Pharmacol 1996;47:591-599.
11. De La Cruz JP, Moreno A, Ruiz-Ruiz MI, Gar-cía Campos JM, Sanchez de la Cuesta F: Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal vascularization in experimental diabetes. Eur J Pharmacol 1998;29:81-85.
12. Cardinal DC, Flower RJ: The electronic aggregometer: A novel device for assessing platelet behaviour in blood. J Pharmacol Methods 1980;3:135-158.
13. Baumgartner HR, Haudenschild C: Adhesion to subendothelium. Ann NY Acad Sci 1972;201:22-36.
14. Baumgartner HR: Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood. Haemostasis 1979;8:340-352.
15. Baumgartner HR, Muggli R: Adhesion and aggregation: Morphological demonstration and quantitation in vivo and in vitro; in Gordon JL (ed): Platelets in Biology and Pathology. Amsterdam, Biomedical Press, 1976, pp 23-60.
16. De La Cruz JP, Bellido I, Camara S, Martos F, Sánchez de la Cuesta F: Effects of acetylsalicylic acid on platelet aggregation in male and female whole blood: An in vitro study. Scand J Haematol 1986;36:394-297.
17. De La Cruz JP, Camara S, Bellido I, Carrasco T, Sánchez de la Cuesta F: Platelet aggregation in human whole blood after chronic administration of aspirin. Thromb Res 1987;46:133-140.
18. López-Farre A, Caramelo C, Esteban A, Alberola ML, Millas I, Monton M, Casado S: Effect of aspirin on platelet-neutrophil interaction: Role of nitric oxide and endothelin-1. Circulation 1995;91:2080-2088.
19. De La Cruz JP, Blanco E, Sánchez de la Cuesta F: Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway. Eur J Pharmacol 2000;397:35-41.
20. De La Cruz JP, Guerrero A, Paniego MJ, Arranz I, Moreno A, Sánchez de la Cuesta F: Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy. Naunyn Schmiedebergs Arch Pharmacol 2002;365:96-101.
21. Perez-Requejo JL, Aznar J, Santos MT, Valles J: Early platelet-collagen interactions in whole blood and their modifications by aspirin and dipyridamole evaluated by a new method (BASIC wave). Thromb Haemost 1985;54: 799-803.
22. De La Cruz JP, Villalobos MA, García PJ, Smith-Agreda JM, Sanchez de la Cuesta F: Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. Eur J Clin Pharmacol 1995;46:497-502.
23. Escolar G, Albors M, Garrido M, Bioque G, Díaz-Ricart M, Carretero M, Ordinas A: Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: Potentiation of antiplatelet effects of aspirin. Eur J Clin Invest 1998;28:562-568.
24. Terres W, Hamm CW, Ruchelka A, Weilip A, Kupper W: Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty. J Cardiovasc Pharmacol 1992;19:190-193.
25. Wolkow PP, Bartus JB, Gryglewski RJ: Pneumotoxicity of lipopolysaccharide in nitric oxide-deficient rats is limited by a thromboxane synthase inhibitor. J Physiol Pharmacol 1997;48:645-653.
26. Olszanecki R, Chlopicki S: Endotoxinaemia in rats: Role of NO, PAF and TxA2in pulmonary neutrophil sequestration and hyperlactataemia. J Physiol Pharmacol 1999;501:443-454.